PDT/Boston Scientific IND filing for drug/catheter combo slated for fourth quarter.
This article was originally published in The Gray Sheet
PDT, INC./BOSTON SCIENTIFIC IND FILING ON DRUG/CATHETER SYSTEM FOR PROSTATE DISEASE is slated for the fourth quarter of this year, PDT says. The drug/catheter combination product, which employs photodynamic therapy to treat benign prostatic hyperplasia and prostate cancer, could enter clinicals by the end of the year following approval of the investigational new drug application, according to the company.
You may also be interested in...
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.